Clinical Trial Update: Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase II study of Pyrotinib as first-line therapy for HER2-amplified/mutated advanced non-small cell lung cancer is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pyrotinib (pyrotinib)

Snippet

Sponsor: Peking Union Medical College Hospital | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: RECRUITING